WuXi Biologics Has Strong Growth Visibility -- Market Talk

Dow Jones03-30

0821 GMT - WuXi Biologics has strong growth visibility and a solid margin profile, HSBC analysts say in a note. They raise their 2026-2027 adjusted net profit forecasts by 4% on likely higher gross margins due to expected rapid increase in high-margin IP-based revenue, increasing capacity utilization and lean operation strategy. HSBC trims its revenue estimates by 1% on headwinds from foreign exchange due to yuan appreciation. HSBC thinks WuXi Biologics's share price, which has been largely flat this year, is undervalued, adding that revenue ramp-up from commercial-stage projects could be a key catalyst. The bank maintains a buy rating but cuts its target price on the stock to HK$44.00 from HK$48.60. Shares closed at HK$31.36. (jason.chau@wsj.com)

(END) Dow Jones Newswires

March 30, 2026 04:21 ET (08:21 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment